Andere Sprachen Qiagen N.V.

Aktien

A400D5

NL0015001WM6

QGEN

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 18.04.2024			Vorbörslich 14:11:43
39,47 ^USD	+0,61 %		39,66	+0,47 %

16.04.	Deutsche Bank Research belässt Qiagen auf 'Buy' - Ziel 50 Dollar	DP
10.04.	Bosch setzt auf Wachstum mit Medizintechnik - neuer Sepsis-Test	RE

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

QIAGEN N.V. to release results for Q1 2024 and hold webcast	09.04.
Qiagen N : launches new solution for screening of sexual assault forensic casework samples	04.04.
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024	03.04.
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	03.04.
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	27.03.
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system	25.03.
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	25.03.
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	18.03.
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements	18.03.
Qiagen N : Virtual Exane Conference Investor Introduction	12.03.
Qiagen N : TD Cowen Healthcare Conference March 5-6 Investor Introduction	12.03.
QIAGEN announces Form 20-F annual report filing for 2023 results	11.03.
For the UK: QIAGEN Ltd statement about the Modern Slavery Act 2015 for 2024	06.03.
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery	27.02.
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	27.02.
Qiagen N : Share buyback program initiated in 2024 2024 Federal-8937 Report of Organizational Actions Affecting Basis of Securities (SSBB)_RS signed	21.02.
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	15.02.
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep	08.02.
QIAGEN : In line Q4; routine business prospects remain intact	07.02.
Dpa-AFX-Überblick: UNTERNEHMEN vom 07.02.2024 - 15.15 Uhr	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

QIAGEN : In line Q4; Routine-Geschäftsaussichten bleiben intakt

Am 07. Februar 2024 um 16:30 Uhr